In the News

Research advances from the National Institutes of Health (NIH) Intramural Research Program (IRP) often make headlines. Read the news releases that describe our most recent findings:

Featured Article

Inside the government study trying to understand the health effects of ultraprocessed foods

Associated Press
March 14, 2025

BETHESDA, Md. (AP) — Sam Srisatta, a 20-year-old Florida college student, spent a month living inside a government hospital here last fall, playing video games and allowing scientists to document every morsel of food that went into his mouth.

From big bowls of salad to platters of meatballs and spaghetti sauce, Srisatta noshed his way through a nutrition study aimed at understanding the health effects of ultraprocessed foods, the controversial fare that now accounts for more than 70% of the U.S. food supply. He allowed The Associated Press to tag along for a day.

“Today my lunch was chicken nuggets, some chips, some ketchup,” said Srisatta, one of three dozen participants paid $5,000 each to devote 28 days of their lives to science. “It was pretty fulfilling.”

Examining exactly what made those nuggets so satisfying is the goal of the widely anticipated research led by National Institutes of Health nutrition researcher Kevin Hall.

“What we hope to do is figure out what those mechanisms are so that we can better understand that process,” Hall said.

NIH, Amgen Foundation and the Foundation for the NIH announce collaboration to support undergraduate research opportunities

Summer research program provides hands-on laboratory experience

Undergraduate students will learn lab work and science leadership skills with mentors from the National Institutes of Health as one of 17 facilities taking part in the Amgen Scholars Program to prepare students for careers in science. Beginning in 2015, NIH will participate as a host institution, appointing candidates who meet both the NIH and Amgen Scholars requirements. This is the first year that NIH will participate in the program in which scholars will spend the summer at NIH’s main campus in Bethesda, Maryland, working with leading scientists. The program is made possible by an $850,000 grant to the Foundation for the NIH from the Amgen Foundation, Thousand Oaks, Calif.

Soldiers at increased suicide risk after leaving hospital

Twelve months following inpatient psychiatric treatment is high-risk period-NIH funded study

U.S. Army soldiers hospitalized with a psychiatric disorder have a significantly elevated suicide risk in the year following discharge from the hospital, according to research from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS External Web Site Policy). The yearly suicide rate for this group, 263.9 per 100,000 soldiers, was far higher than the rate of 18.5 suicides per 100,000 in the Regular Army for the same study period, the study found.

Soldiers at increased suicide risk after leaving hospital

Diversity Outbred mice better predict potential human responses to chemical exposures

A genetically diverse mouse model is able to predict the range of response to chemical exposures that might be observed in human populations, researchers from the National Institutes of Health have found. Like humans, each Diversity Outbred mouse is genetically unique, and the extent of genetic variability among these mice is similar to the genetic variation seen among humans.

Diversity Outbred mice better predict potential human responses to chemical exposures

This National Diabetes Month, take steps to improve diabetes outcomes

NIH statement from Dr. Griffin P. Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases

More than 29 million Americans have diabetes, and about 86 million more are on the verge of the disease. People with diabetes are nearly two times more likely than people without diabetes to die from heart disease, and are also at greater risk for kidney, eye and nerve diseases, among other painful and costly complications.

This year, in observance of National Diabetes Month, including World Diabetes Day on Nov. 14, The National Institutes of Health asks people to take to heart the lessons learned from our research. Type 2 diabetes can be delayed or prevented, and both types 1 and 2 diabetes can be managed to prevent complications.

NIH-led study explores prevention of heart disease in HIV-infected people

The National Institutes of Health has launched a clinical trial to assess the effects of aspirin and cholesterol-lowering drugs, or statins, on preventing cardiovascular disease in people with long-term HIV infections. This group, which includes people on antiretroviral therapy (ART) as well as “elite controllers” who can limit the virus without ART, have a higher risk of developing heart disease and stroke compared to the general population. The study is funded by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Texas nurse free of Ebola virus; discharged from NIH Clinical Center

The NIH Clinical Center has discharged Ms. Nina Pham, the Texas nurse who was admitted on Thursday, October 16, with Ebola virus disease, after confirming that she is now free of the virus. It is critical to remember that people who have survived Ebola are not contagious and can no longer spread disease. We would not be releasing Ms. Pham if we were not completely confident in the knowledge that she has fully recovered, is virus free and poses no public health threat. The healthcare team at the NIH is pleased to have had the opportunity to provide care to Ms. Pham and guide her recovery. We extend our best wishes to her as she continues to regain her strength and return to normal life.

Texas nurse free of Ebola virus; discharged from NIH Clinical Center

NIH begins early human clinical trial of VSV Ebola vaccine

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. The Walter Reed Army Institute of Research (WRAIR) is simultaneously testing the vaccine candidate as a single dose at its Clinical Trials Center in Silver Spring, Maryland.

Update on Clinical Status of Ebola Patient at the NIH Clinical Center

The NIH has received countless inquiries and expressions of support for Ms. Nina Pham, the Texas nurse who was admitted to the NIH Clinical Center Special Clinical Studies Unit on Thursday, October 16, with Ebola virus disease. The NIH Clinical Center staff has shared the general sentiments with her and Ms. Pham has expressed her gratitude for everyone’s concerns and well wishes. Ms. Pham’s clinical status has been upgraded from fair to good. No additional details are available at this time.

Shaking up cell biology

Researchers focus in on decades old mystery

Mitochondrial oscillations have quietly bewildered scientists for more than 40 years. Now, a team of scientists at National Institutes of Health’s National Institute of Dental and Craniofacial Research (NIDCR) has imaged mitochondria for the first time oscillating in a live animal, in this case, the salivary glands of laboratory rats. The report, published online today in the journal Cell Reports, shows the oscillations occur spontaneously and often in the rodent cells, which leads the researchers to believe the oscillations almost surely also occur in human cells.

Shaking up cell biology

Rapid agent restores pleasure-seeking ahead of other antidepressant action

Depression deconstructed — NIH study

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of — and ahead of — its other antidepressant effects, in a National Institutes of Health trial. Within 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom — loss of interest in pleasurable activities — which lasted up to 14 days. Brain scans traced the agent’s action to boosted activity in areas at the front and deep in the right hemisphere of the brain.

Rapid agent restores pleasure-seeking ahead of other antidepressant action

Continue Exploring the IRP

This page was last updated on Friday, March 21, 2025